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Among diet components, some fatty acids are known to affect several stages of colon carcinogenesis, whereas others are probably
helpful in preventing tumors. In light of this, our aim was to determine the composition of fatty acids and the possible correlation
with apoptosis in human colon carcinoma specimens at different Duke’s stages and to evaluate the effect of enriching human
colon cancer cell line with the possible reduced fatty acid(s). Specimens of carcinoma were compared with the corresponding non-
neoplastic mucosa: a significant decrease of arachidonic acid, PPARα, Bad, and Bax and a significant increase of COX-2, Bcl-2,
and pBad were found. The importance of arachidonic acid in apoptosis was demonstrated by enriching a Caco-2 cell line with this
fatty acid. It induced apoptosis in a dose- and time-dependent manner via induction of PPARα that, in turn, decreased COX-2. In
conclusion, the reduced content of arachidonic acid is likely related to carcinogenic process decreasing the susceptibility of cancer
cells to apoptosis.
Copyright © 2009 Manuela Oraldi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Introduction
Colon carcinoma is one of the world’s most widespread
tumors and appears to be correlated with diet [1]. Although
the disease may evolve from genetic alterations in pro-
tooncogenes or tumor suppressor genes [2], there is evidence
indicating that some dietary factors, such as fat and fiber,
can also affect several stages of colon carcinogenesis [3, 4].
Among diet components, lipids are perceived as dangerous,
although some lipids, such as certain polyunsaturated fatty
acids (PUFAs), are considered to be positive for human
health, preventing tumors and cardiovascular diseases [5–
7]. Thus dietary adjustment aimed at preventing colorectal
carcinoma is increasingly becoming an interesting option
[8].
However, little is known about the composition of fatty
acids in human colon carcinoma tissue versus that of non-
neoplastic mucosa or about any changes in this composition
during tumor development. Some findings have shown a
decrease in PUFAs, such as linoleic and α-linolenic acids,
together with an increase in free arachidonic acid, in colon
cancer tissue versus those of a normal human large intestine,
whereas other data have indicated an increase in linoleic
acid and a decrease in α-linolenic and arachidonic acids
[9–11].
More is known about the effect of PUFAs on cell
lines and on the development of carcinoma in animals
models. Supplementing cell lines with n-3 or n-6 PUFAs
leads to an increased incorporation of these PUFAs in
membrane phospholipids, influencing not only cell structure
but also cell functions, including immunological response,
proliferation, and survival [12–15]. Feeding animals with n-
3 PUFAs has been found to inhibit tumor growth, probably
because of the altered fatty acid composition [16, 17].
The effects of PUFAs on cell function and viability may
be related to the fact that they and their metabolites are
important mediators of the intracellular signal networks;
that is, they may have an effect on gene expression after
binding with peroxisome proliferator activated receptors
(PPARs). PPARs are present in cells in three isoforms (α,β, γ)
and play an important regulatory role in lipid metabolism
and cancer development [15, 18, 19].
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Among PUFA metabolites, the prostaglandines (PGs),
which are derived from arachidonic acid, have been studied
in depth. The PGE2 level has been shown to be significantly
elevated during inflammation and in cancer, and this finding
has been attributed to the increased expression of the
inducible cyclo-oxygenase 2 (COX-2) [20]. The functions of
COX-2-derived PGE2 in malignant and metastatic disease
have been widely studied, and it appears to play a role
in tumor invasion, in stimulating angiogenesis, and in
modulating apoptosis [21, 22].
There is considerable controversy over the frequency of
apoptotic cell death in the adenoma-carcinoma sequence
in the human colon. Most researchers have found that the
apoptotic index was higher in carcinoma than in normal
colonic mucosa and adenomas, even though Tsujitani et al.
reported a lower apoptotic rate in carcinoma, in a study
comparing carcinomatous with adenomatous components
in the same tumors [23, 24].
In light of the limited knowledge of the apoptotic
events in colon cancer, and since PUFAs can modulate
cancer development by regulating cell proliferation and/or
viability, this study examined specimens of human colon
carcinoma at different stages of Duke’s classification and
the corresponding non-neoplastic mucosa. The aim was to
evaluate any changes in fatty acid content of phospholipids,
in expression of some proteins regulating apoptosis and in
PPARα, whose fatty acids are ligands. COX-2, the enzyme
responsible for the production of fatty acid metabolites active
in cancer induction, was also analyzed.
To corroborate the results obtained in vivo, human colon
carcinoma Caco-2 cells were used to evaluate the effect of
arachidonic acid, an ω-6 fatty acid, in modulating apoptosis.
2. Materials and Methods
2.1. Colon Tissue Specimens. Colon adenocarcinoma and
adjacent non-neoplastic colonic mucosa specimens were
obtained from 28 surgical patients at the Oncology Center,
Molinette Hospital, Turin, Italy. Adjacent connective tissue
was stripped away in all cases, to ensure that there was no
fat contamination, and colonic cancer specimens were free of
non-neoplastic colon mucosa. Specimens were immediately
frozen and stored at −80◦C. Resected cancers were staged,
according to Duke’s classification, as A in 3 cases, B in 8 cases,
C in 11 cases and D in 6 cases.
Human samples were collected and analyzed with the
full understanding and consent of the patient. Responsible
Ethical Committee has approved these experiments.
2.2. Cell Cultures. Human colon cancer cells Caco-2 (ATCC,
USA) were seeded (30 000 cells/cm2) and maintained for
48 hours in DMEM+GlutaMAX-1 medium containing 1%
antibiotic/antimycotic solution (medium A), supplemented
with 10% fetal bovine serum (FBS), and maintained at 37◦C
in a humidified atmosphere of 95% air and 5% CO2.
2.3. Caco-2 Cell Differentiation. Cells were maintained in
culture for 2 and 20 days. After harvesting the cells were
examined for arachidonic acid percentage content and
for alkaline phosphatase (ALP) activity as differentiation
marker. ALP activity was determined as in [25].
2.4. Arachidonic Acid Supplementation. A stock solution
of free arachidonic acid (100 mM in FBS) was prepared
and stored at −20◦C until use. Twenty four hours after
seeding undifferentiated cells, culture medium was removed
and replaced by medium B (medium A plus 0.4% serum
bovine albumin (fatty acid free), 1% vitamin solution,
1% nonessential amino acids) supplemented or not with
arachidonic acid (time 0). Arachidonic acid stock solution
was diluted to the final concentration directly in medium B,
used to replace medium A. FBS alone was added to control
cells.
At the experimental times indicated in the figures, Caco-
2 cells, treated or not with arachidonic acid, were trypsinized
after collecting culture medium, harvested and centrifuged at
600 g for 10 minutes, to determine apoptosis parameters.
2.5. Treatment of Cells with PPARα Antagonist MK886 or
with COX-2 Inhibitor NS398. Caco-2 cells were treated
with arachidonic acid, as described above, and with the
PPARα antagonist MK886 or COX-2 inhibitor NS398. 2μM
MK886 was administered to the cells when arachidonic acid
was added (time 0), and 50μM NS398 one hour before
arachidonic acid addition.
2.6. Apoptosis Evaluation. Percentages of viable, necrotic,
or apoptotic cells were evaluated by determining the DNA
content after propidium iodide staining in flowcytometry as
described in [18].
The presence of apoptotic cells was also shown by
staining cells with DAPI (4′, 6-diamidino 2-phenylindole)
then observing them using fluorescence microscopy.
2.7. Analysis of Fatty Acid Composition in Phospholipids. The
percentage content of different fatty acids was determined
in the polar lipids extracted from non-neoplastic and colon
cancer specimens and from Caco-2 cells as described in [19].
The percentage of single fatty acids was calculated taking the
content of total fatty acids in phospholipids as 100%. Methyl
heptadecanoate was added to each preparation as internal
standard.
2.8. Western Blot Analysis. For each colon specimen, about
50 mg of tissue was washed twice in cold PBS and then
homogenized by sonication in 150μL of Totex buffer (pH
7.9) containing 20 mM Hepes, 350 mM NaCl, 20% glyc-
erol, 1% NP-40 substitute, 1 mM MgCl2, 0.5 mM EDTA,
0.1 mM EGTA, 1 mM Na-orthovanadate, 1 mM phenyl
methyl sulfonyl fluoride (PMSF), 5 mM DL-Dithiothreitol,
and 15μg/mL leupeptin. The homogenates were kept on
ice for 1 hour and then centrifuged in a microfuge at
13500 rpm for 25 minutes. Supernatants containing the
extracted proteins were then collected and used for Western
blot analysis as described in [18].
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Figure 1: Protein content of COX-2, PPARα, and Bcl-2 in cancer specimens and corresponding non-neoplastic mucosa. The densitometry
value for PPARα and Bcl-2, referred to the corresponding β-actin value, was compared with that of the corresponding non-neoplastic
mucosa, taken as 1. The data are expressed in means ± SD. Since COX-2 was not expressed in all mucosa specimens, the same comparative
data as for PPARα is not available. Significant differences between cancer specimens and relative mucosa specimens were assessed by the
Wilcoxon signed rank test (∗P < .05). Significant differences among cancer groups at different Duke’s stages were assessed by variance
analysis followed by the post hoc Newman-Keuls test. C+: positive control.
The membranes were incubated with polyclonal anti-
PPARα, Bcl-2, pBAD, BAD and Bak, with monoclonal
anti-COX-2 (all purchased from Santa Cruz Biotechnology,
Heidelberg, Germany), or anti- β-actin (purchased from
Sigma, Mo, USA) antibodies. The densitometry value for
each protein was referred to the corresponding β-actin value.
Collected Caco-2 cells were suspended to 50% (w/v) in
lysis buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM
NaCl, 5 mM EDTA, 1% NP-40 substitute, 1 mM PMSF, 1 mM
Na-orthovanadate, and 15μg/mL leupeptin. Cells were then
incubated for 30 minutes on ice and sonicated 3 times for
3 seconds. After centrifugation, the extracted proteins were
used for Western blot analysis as described above. PPARα,
Bcl-2, Bak, and COX-2 were evaluated.
2.9. Protein Determination. Protein content was determined
with the Protein Assay Kit 2 (BIO-RAD Laboratories, CA,
USA).
2.10. Statistical Analysis. Data for fatty acid percentage
content in cancer and corresponding mucosa specimens are
expressed as means ± SD. Significant differences between
all cancer and their corresponding mucosa specimens, and
those among cancer groups at different stages of Duke’s
classification, were assessed by variance analysis, followed by
the post hoc Newman-Keuls test.
Protein content data are expressed as means ± SD,
calculated by relating the values in cancer specimens to
those in mucosa ones, taken as 1. Significant differences
between cancer and the corresponding mucosa specimens
were assessed by the Wilcoxon signed rank test; significant
differences among cancer groups at different stages of Duke’s
classification were assessed by variance analysis, followed by
the post-hoc Newman-Keuls test.
Significant differences between Caco-2 cells treated with
arachidonic acid or untreated were assessed by variance
analysis, followed by post hoc Newman-Keuls test.
3. Results
3.1. Human Colon Cancer Specimens
3.1.1. Colon Cancer Classification. Colon non-neoplastic
mucosa and carcinoma specimens were obtained from 28
surgical patients (15 women, 13 men; age range 32 to 87
years; mean 67.50 ± 11.69). Carcinomas ranged from well
to poorly differentiated and were at the following stages of
Duke’s classification: 3 cases of resected cancers were in stage
A, 8 cases in B, 11 cases in C, and 6 cases in D.
3.1.2. Fatty Acid Composition in Phospholipids. Table 1
reports the percentage of the content of various PUFAs in
phospholipids extracted from cancer specimens at different
Duke’s stages and from the corresponding non-neoplastic
mucosa. Table 1 also reports the sum (
∑
) of PUFAs and of
monounsaturated fatty acids (MUFAs) plus saturated fatty
acids. The table also shows the significance of differences
between mucosa and tumor specimens; the significance
among tumor specimens at different Duke’s stages was not
reported, since there were no differences.
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Table 1: Percentage of the content of polyunsaturated fatty acids in phospholipids extracted from colon cancer specimens and corresponding
non-neoplastic mucosa.
Fatty acids
A B C D
Mucosa Tumour Mucosa Tumour Mucosa Tumour Mucosa Tumour
18 : 2 12.5 9.1 10.1 8.9 12.1 10.7 12.5 7.6∗
18 : 3 0.2 0.7 0.4 0.3 1.0 1.1 0.8 0.6
CLA 0.5 0.5 1.4 0.2∗ 1.2 0.5∗ 0.7 0.2∗
20 : 4 11.0 7.1∗ 11.4 8.1∗ 11.6 7.7∗ 13.4 9.5∗
22 : 6 1.0 1.5 1.8 1.5 1.6 1.8 2.4 1.9
∑
PUFA 25.2 18.9∗ 25.1 19.0∗ 27.6 21.3∗ 29.9 19.8∗
∑
MUFA + saturated 74.8 81.1∗ 74.9 81.1∗ 72.4 78.7∗ 70.1 80.2∗
The SD was not more than 10%. For each fatty acid, the variance analysis followed by post hoc Newman-Keuls test was carried out. The table only shows the
significance of differences between mucosa and tumor specimens (∗ tumour versus mucosa, P < .05). The differences among tumour specimens at different
Duke’s stages (A, B, C, D) were not significant.
∑
PUFA: sum of all polyunsaturated fatty acids;
∑
MUFA + saturated: sum of all monounsaturated and saturated fatty acids.
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Figure 2: Protein content of Bak, Bad, and p-Bad in cancer specimens and corresponding non-neoplastic mucosa specimens. The
densitometry values, the data, and significant differences are as in Figure 1.
Comparing the percentage of the content of each PUFA
in cancer specimens and in the corresponding mucosa,
a significant decrease was seen in arachidonic acid at all
Duke’s stages, for linoleic acid at stage D, and for CLA
at stages B, C, and D. On the contrary, no difference was
found for linolenic or docosaexaenoic acids. The decreases
in linoleic and arachidonic acids and in CLA accounted for
the decreased
∑
PUFA content observed at all Duke’s stages.
3.1.3. COX-2 Content. In view of the decreased arachidonic
acid percentage, the protein content of COX-2 was evaluated.
It was found to be increased in cancer specimens versus
mucosa specimens. Figure 1 shows a typical COX-2 Western
blot: the protein was not expressed in non-neoplastic mucosa
and was increased in carcinoma at all stages. Since COX-
2 was not expressed in all mucosa specimens, the same
comparative data are not available for this protein.
3.1.4. PPARα Content. Since fatty acids and their metabolites
are preferential ligands of PPARα, the protein content of
this nuclear receptor was evaluated (Figure 1), showing a
decrease in carcinoma versus mucosa at all Duke’s stages with
no significant differences among Duke’s stages.
3.1.5. Apoptosis Parameters. The antiapoptotic protein Bcl-2
and inactive phosphorylated form of Bad (Figures 1 and 2)
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Figure 3: Percentage of the content of arachidonic acid and
percentage of cells in apoptosis in human Caco-2 cells 48 hours after
enrichment with arachidonic acid. Data are expressed in means ±
SD of 4 experiments. For arachidonic acid and for apoptosis means
with different letters are significantly different from one another
(P < .05), as determined by variance analysis followed by post hoc
Newman-Keuls test. For percentage of the content of arachidonic
acid; diff: differentiated Caco-2 cells; undiff: undifferentiated Caco-
2 cells; undiff + AA25: undifferentiated Caco-2 cells treated with
25μM arachidonic acid; undiff + AA50: undifferentiated Caco-
2 cells treated with 50μM arachidonic acid; undiff + AA100:
undifferentiated Caco-2 cells treated with 100μM arachidonic acid.
For percentage of cells in apoptosis: C: control cells; AA25: cells
treated with 25μM arachidonic acid; AA50: cells treated with 50μM
arachidonic acid; AA100: cells treated with 100μM arachidonic
acid; MK: cells treated with 2μM MK886.
were increased in all cancer specimens, with no differences
among Duke’s stages, whereas the proapototic proteins Bad
and Bak were decreased (Figure 2).
3.2. Human Colon Cancer Cells Caco-2
3.2.1. Arachidonic Acid Content. Figure 3 shows the percent-
age content of fatty acids in phospholipids extracted from
differentiated and undifferentiated Caco-2 cells, showing that
arachidonic acid is present in higher percentage content in
differentiated cells than in undifferentiated cells (3.7 versus
9.4, resp.). Enriching undifferentiated cells with 25, 50, or
100μM arachidonic acid, the percentage content of this
fatty acid increased reaching a value of 15 with 100μM
arachidonic acid.
C
AA25
AA50
AA100
MK886
AA25 + MK
AA50 + MK
AA100 + MK
Figure 4: Apoptosis in human Caco-2 cells 48 hours after enrich-
ment with arachidonic acid. Apoptosis was determined by staining
the cells with DAPI. C: control cells; AA25: cells treated with 25μM
arachidonic acid; AA50: cells treated with 50 μM arachidonic acid;
AA100: cells treated with 100μM arachidonic acid; MK: cells treated
with 2μM MK886.
3.2.2. Apoptosis and PPARα Content. The increased arachi-
donic acid content in treated-cells affected cell viability,
inducing apoptosis, as shown in Figure 3. Apoptosis was
also shown by DAPI staining (Figure 4): arachidonic acid-
treated cells showed fragmented and condensed nuclei, and
apoptotic bodies; on the contrary, in untreated cells few
apoptotic figures were observed.
The involvement of arachidonic acid in modulating
apoptosis was confirmed by analyzing the antiapoptotic
protein Bcl-2 and the proapoptotic proteins Bak and caspase
3. Figure 5 shows a decrease of the first protein and an
increase of the second ones in arachidonic-treated cells in
comparison with control cells. Caspase 3 induction was
shown by an increased amount of cleaved form.
Figure 6 reports the PPARα content, demonstrating
an increase of this nuclear receptor in treated cells. Its
involvement in arachidonic acid-induced apoptosis was
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Figure 5: Protein content of Bcl-2, Bak, and caspase 3 in Caco-2 cells 48 hours after enrichment with arachidonic acid. Data are expressed in
means ± SD of 4 experiments. Means with different letters are significantly different from one another (P < .05), as determined by variance
analysis followed by post hoc Newman-Keuls test. The densitometry values, referred to as the corresponding β-actin value, were compared
with those of control cells, taken as 1. C: control cells; AA25: cells treated with 25 μM arachidonic acid; AA50: cells treated with 50 μM
arachidonic acid; MK: cells treated with 2 μM MK886.
demonstrated by treating the cells with the specific PPARα
antagonist MK886. Figures 3 and 4 show that MK886
prevented apoptosis induction and growth inhibition due
to arachidonic acid. The reverting effect of MK886 was
also confirmed by DAPI staining. The prevention of
apoptosis induction was further confirmed by evalua-
tion of anti- and proapoptotic proteins (Figure 5). Bcl-
2 level was increased in the cells treated with arachi-
donic acid and MK886 in comparison with the cells
treated with arachidonic acid alone, whereas Bak was
decreased.
3.2.3. COX-2 Content. The evaluation of COX-2 in Caco-2
cells enriched with arachidonic acid showed that the lowest
concentration of fatty acid slowly increased the enzyme
content, whereas the highest concentration decreased it
(Figure 6). PPARα antagonist MK886, which did not
induce apoptosis, increased COX-2 content. To demon-
strate that COX-2 was involved in blocking apoptosis,
specific COX-2 inhibitor NS398 was used, showing that
it increased apoptotic cell percentage in comparison with
untreated cells. Cells treated with both arachidonic acid
and COX-2 inhibitor showed a further increase in apoptosis
(Figure 6).
4. Discussion
The study is focused on the fatty acid content in phospho-
lipids of human colon cancer samples of different degrees of
malignancy and on some factors regulating apoptosis. The
observations suggested by the results obtained with cancer
specimens were confirmed using “in vitro” experiments
using Caco-2 cells.
The most significant differences between colon cancer
specimens and the corresponding non-neoplastic mucosa
were as follows: (1) the percentage of the content of
∑
PUFAs, linoleic acid, CLA, and arachidonic acid decreased;
(2) COX-2 increased in cancer specimens, whereas in
non-neoplastic mucosa it was not expressed; (3) PPARα
decreased; (4) the antiapoptotic proteins Bcl-2 and pBad
increased, whereas the proapototic proteins Bad and Bak
decreased.
The results in cancer specimens were also correlated
with the patients’ clinical stage but showed no evidence
that the clinical stage influenced the parameters examined.
In view of this, it is possible to hypothesize that changes
in some parameters, such as PUFA and proteins involved
in apoptosis, are important for the entire carcinogenesis
process.
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Figure 6: Protein content of PPARα and COX-2 and percentage of cells in apoptosis in human Caco-2 cells 48 hours after enrichment with
arachidonic acid and COX-2 inhibitor NS398. Data are expressed in means± SD of 3 experiments. For COX-2 and for apoptosis means with
different letters are significantly different from one another (P < .05), as determined by variance analysis followed by post hoc Newman-Keuls
test. For PPARα and COX-2, the densitometry values, referred to as the corresponding β-actin value, was compared with those of control
cells, taken as 1. C: control cells; AA25: cells treated with 25 μM arachidonic acid; AA50: cells treated with 50 μM arachidonic acid; MK: cells
treated with 2 μM MK886. For percentage of cells in apoptosis, C: control cells; AA50: cells treated with 50 μM arachidonic acid; NS: cells
treated with 50 μM NS398; AA50 + NS: cells treated with 50 μM arachidonic acid plus 50 μM NS398.
The low arachidonic acid content present in colon cancer
was also evident in undifferentiated Caco-2 cells. It is
noteworthy that the content of this fatty acid in Caco-2 cells
is in relation to the degree of deviation. In fact, its percentage
was lower in undifferentiated cells than in differentiated cells,
pointing again to the importance of arachidonic acid in the
development of tumours.
The reduced content of arachidonic acid might be also
considered a defense mechanism whereby cancer cells protect
themselves from the cytotoxic effect of this compound. In
fact, the low level of arachidonic acid was accompanied
by an increase in antiapoptotic protein Bcl-2 and by the
reduction of proapototic proteins and PPARα, indicating a
decreased susceptibility to apoptosis in colon cancer with
respect to non-neoplastic mucosa. This correlation between
arachidonic acid and susceptibility to apoptosis, to which
these “in vivo” results point, was supported by “in vitro”
experiments, in which exogenously added arachidonic acid
was found to cause apoptosis in colon cancer Caco-2 cells.
Cell death was found to be correlated with the intracellular
level of arachidonic acid. The induction of apoptosis by
arachidonic acid has also been confirmed by other authors
[26].
The decreased percentage of arachidonic acid in tumors
at all Duke’s stages was probably correlated with the
increased expression of COX-2. Previous studies have shown
this enzyme to be increased in colon and rectal cancer [27],
and to not be expressed in non-neoplastic mucosa [27]. The
importance of COX-2 in modulating colon carcinogenesis
has been shown by the observation that NSAIDs prevent
colon cancer and cause apoptosis [28]. The apoptosis-
inducing mechanism might result from the accumulation
of the COX substrate, arachidonic acid, which is a strong
signal for induction of apoptosis: COX-2 may promote
carcinogenesis by lowering the arachidonic acid level and
producing PGE2 [29]. Also “in vitro” results shown here
confirmed that COX-2 inhibitor induces apoptosis.
The mechanism triggered by arachidonic acid which
leads to apoptosis may be ascribed to PPARα modulation.
In fact, the decreased PPARα in tumor specimens compared
to non-neoplastic mucosa was supported by our “in vitro”
study supporting a direct correlation between PPARα and
apoptosis. The inverse correlation between PPARα and COX-
2 shown “in vivo” was confirmed by “in vitro” experiments,
where the highest arachidonic acid concentration, deter-
mining the highest PPARα content, was accompanied by
8 Journal of Oncology
a decrease of COX-2 content. This observation supports with
other authors’ studies reporting that PPARα ligands inhibit
COX-2 expression by directly antagonizing NFkB- and AP-
1-mediated signalling pathways [30].
The decrease of PPARα in tumors confirms the obser-
vation of other authors that a significant decrease in its
expression is found in human tubular adenomas compared
to normal human colonic epithelial cells [29]. Moreover, the
importance of PPARα in apoptosis has also been seen by
other “in vitro” studies [18, 31], stimulating interest in the
investigation of PPARα as a possible therapeutic target to
prevent colon cancer formation.
5. Conclusions
The bulk of both “in vivo” and “in vitro” results strongly sug-
gests that colon cancer cells are characterized by decreased
susceptibility to apoptosis deriving from decreased arachi-
donic acid content, PPARα and proapoptotic proteins, and
increased antiapoptotic proteins and COX-2.
In fact, colon cancer in humans shows a modified fatty
acid composition in phospholipids, with a reduction in
arachidonic acid content. These changes are associated with
an increase in survival-related parameters. The reduced con-
tent of arachidonic acid is likely related to the carcinogenic
process and protects against the effects of oxidative stress
products, decreasing the susceptibility of cancer cells to
apoptosis. This last observation was supported by treating
Caco-2 cells with arachidonic acid.
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